Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML) and Cataloging the Molecular Consequences of JAK2 Inhibition in Chronic Myelomonocytic Leukemia: A Correlative Study Identifying Targetable CMML Sub-Clones by Leveraging GM-CSF Dependent pSTAT Hypersensitivity

Trial Profile

A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML) and Cataloging the Molecular Consequences of JAK2 Inhibition in Chronic Myelomonocytic Leukemia: A Correlative Study Identifying Targetable CMML Sub-Clones by Leveraging GM-CSF Dependent pSTAT Hypersensitivity

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Jun 2019

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Chronic myelomonocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 03 Jun 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Dec 2019.
    • 02 Jan 2019 Planned primary completion date changed from 1 Apr 2019 to 1 Jun 2019.
    • 28 Mar 2018 Planned End Date changed from 1 Jul 2019 to 1 Apr 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top